The efficacy and safety of mizoribine for maintenance therapy in patients with myeloperoxidase anti-neutrophil cytoplasmic antibody (MPO-ANCA)-associated vasculitis: the usefulness of serum mizoribine monitoring

被引：0
作者：
Kaori Mase
Chie Saito
Joichi Usui
Yoshihiro Arimura
Kosaku Nitta
Takashi Wada
Hirofumi Makino
Eri Muso
Nobuhito Hirawa
Masaki Kobayashi
Wako Yumura
Shouichi Fujimoto
Naoki Nakagawa
Takafumi Ito
Yukio Yuzawa
Seiichi Matsuo
Kunihiro Yamagata
机构：
[1] University of Tsukuba,Department of Nephrology, Faculty of Medicine
[2] Kyorin University School of Medicine,Department of Nephrology and Rheumatology
[3] Kichijoji Asahi Hospital,Department of Medicine
[4] Kidney Center,Department of Nephrology and Laboratory Medicine
[5] Tokyo Women’s Medical University,Department of Nephrology and Dialysis
[6] Kanazawa University,Department of Nephrology and Hypertension
[7] Okayama University,Department of Nephrology
[8] Kitano Hospital,Department of Hemovascular Medicine and Artificial Organs, Faculty of Medicine
[9] Tazuke Kofukai Medical Research Institute,Division of Cardiology, Nephrology, Respiratory and Neurology, Department of Internal Medicine
[10] Yokohama City University Medical Center,Division of Nephrology
[11] Tokyo Medical University Ibaraki Medical Center,Department of Nephrology
[12] Department of Nephrology,undefined
[13] Jichi Medical School,undefined
[14] University of Miyazaki,undefined
[15] Asahikawa Medical University,undefined
[16] Shimane University Hospital,undefined
[17] Fujita Health University School of Medicine,undefined
[18] Nagoya University,undefined
来源：
Clinical and Experimental Nephrology | 2022年 / 26卷
关键词：
MPO-ANCA-associated vasculitis (MPO-AAV); Mizoribine; Serum immunosuppressive drugs concentration;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1092 / 1099
页数：7
相关论文
共 67 条
  • [1] Jennette JC(2013)2012 revised international chapel hill consensus conference nomenclature of vasculitides Arthritis Rheum 65 1-11
  • [2] Falk RJ(2021)2021 American college of rheumatology/vasculitis foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis Arthritis Rheum 73 1366-1383
  • [3] Bacon PA(2016)EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis Ann Rheum Dis 75 1583-1594
  • [4] Chung SA(2009)Japan RPGN registry group. A nationwide survey of rapidly progressive glomerulonephritis in Japan: etiology, prognosis and treatment diversity Clin Exp Nephrol 13 633-650
  • [5] Langford CA(2012)ANCA-associated systemic vasculitis in Japan: clinical features and prognostic changes Clin Exp Nephrol 16 580-588
  • [6] Maz M(2019)Temporal change in life and renal progressive glomerulonephritis in Japan via nationwide questionnaire survey Clin Exp Nephrol 23 573-575
  • [7] Yates M(2020)Correction to: temporal change in life and renal progressive glomerulonephritis in Japan via nationwide questionnaire survey Clin Exp Nephrol 24 976-977
  • [8] Watts RA(1974)Studies on bredinin. I. Isolation, characterization and biological properties J Antibiot 27 775-782
  • [9] Bajeme IM(2002)Mizoribine: mode of action and effects in clinical use Pediatr Int 44 196-198
  • [10] Koyama A(2004)Treatment with the purine synthesis inhibitor mizoribine for ANCA-associated renal vasculitis Am J Kidney Dis 44 57-63
1234567